COGT - Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment | Benzinga
Cogent Biosciences Inc (NASDAQ: COGT) shared data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) at the American Society of Hematology Annual Meeting & Exposition.
As of the Sept. 25, 2023 data cutoff, bezuclastinib demonstrated a differentiated safety and tolerability profile across doses.
Most adverse events were low-grade and reversible, and no related cognitive impairment or bleeding events were reported. Related serious adverse events were reported in four patients.
As of the data cutoff date of Sept. 25, 2023, 32 patients enrolled were evaluated for signs of clinical activity:
A ...